INS, B Cells and Microbiota

Launched by NANTES UNIVERSITY HOSPITAL · Jun 8, 2021

Keywords

ClinConnect Summary

The clinical trial titled "INS, B Cells and Microbiota" is investigating a kidney condition called idiopathic nephrotic syndrome (NIS), which causes high levels of protein in the urine and can lead to kidney failure. The researchers are particularly interested in the role of certain immune cells (B lymphocytes) and the bacteria in our gut (microbiota) in the development and flare-ups of this condition. They believe that changes in these immune cells and gut bacteria may contribute to the disease, especially in children.

To participate in this trial, individuals must be currently experiencing a nephrotic attack, defined by specific levels of protein in their urine. However, those with a history of severe flare-ups that do not respond to standard steroid treatments, or who are currently on certain medications, are not eligible. Participants can expect to receive close monitoring and treatment during the study, which could help improve understanding of how the immune system and gut health influence this kidney disease. This research is important because it aims to find better ways to treat and manage NIS, potentially leading to improved outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • Patient treated in participating centers
• * In nephrotic attack, defined biologically by:
• • Proteinuria \> 3g 24h or A proteinuria/creatinuria ratio \> 3 or Defined at the discretion of the clinician
• Non inclusion Criteria :
• • Patient with a history of NIS flare-ups resistant to corticosteroid therapy
• • Patient treated with immunosuppressant
• • Patient treated with corticosteroids \> 10 mg/d
• • Weight \<50 kg
• • Pregnant woman
• • Patient under guardianship / curatorship